John Jesitus
Abstract
Topical ivermectin cream 1 percent has shown safety and statistically superior efficacy versus vehicle as early as week two of treatment in phase 3 trials.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Topical ivermectin cream 1 percent has shown safety and statistically superior efficacy versus vehicle as early as week two of treatment in phase 3 trials.
Key concepts: Rosacea, Medicine, Ivermectin, Dermatology, Onchocerciasis, Clinical pharmacology, Topical agents, Acne